Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

AZ shutters R&D unit in India

Local reports says pharma company will transfer operations to UK and outsourcing partners

Bristol-Myers Squibb (BMS) building

BMS shares fall on nivolumab jitters despite solid Q4 results

Awaiting data from ongoing studies before advancing cancer prospect

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

AZ’s Soriot upbeat on firm’s prospects

Says pharma company can return to growth by 2017

- PMLiVE

FDA sets standard review for Gilead’s idelalisib in NHL

Comes despite accelerated review for drug’s use in chronic lymphocytic leukaemia

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

- PMLiVE

AstraZeneca buys BMS out of diabetes alliance

Will spend up to $4.3bn to secure sole rights to Onglyza and Forxiga

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links